Clinical trial · Observational
Clonal Hematopoiesis of Immunological Significance
Immuno-inflammatory Manifestations With or Without Clonal Hematopoiesis: Ambispective Cohort Study
NCT05969821CI-TRIAL-00106239CHISnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autoimmune Diseases | — | UNRESOLVED | — |
| Autoinflammatory Diseases | — | UNRESOLVED | — |
| Clonal Hematopoiesis of Indeterminate Potential | — | UNRESOLVED | — |
| Hematologic Diseases | — | UNRESOLVED | — |
| Hematopoiesis Clonal | — | UNRESOLVED | — |
| Immune System Diseases | — | UNRESOLVED | — |
| Inflammation | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Leukemia Myelomonocytic Chronic | Chronic Myelomonocytic Leukemia | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational cohort study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Dysimmune manifestations with or without clonal hematopoiesis
- description
- Dysimmune manifestations with or without clonal hematopoiesis
- interventionNames
- Other: observational cohort study
Primary outcomes (1)
- measure
- Incidence of dysimmune manifestations associated with hematological disorders
- timeFrame
- Baseline
- description
- Number of new cases
Secondary outcomes (17)
- measure
- VEXAS syndrome
- timeFrame
- 10 years
- description
- Number of patients with VEXAS syndrome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>=18 years old; * Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease; * Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification Exclusion Criteria: * Persons benefiting from special protection: adults under guardianship and curatorship; * People hospitalized without their consent and not protected by law; persons deprived of liberty; * Persons not affiliated to the social security system
References
Publications (0)
Data not yet available
No reference posted for this study.